focus
Editor’s note: A recording of the event is embedded below.
After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
advertisement
Featured Speakers
- Irena Melnikova, Ph.D., partner, Pfizer Ventures
- Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
- Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
The SUPPORT Act is critical to fighting the opioid crisis
Next article： Supreme Court strikes down use of affirmative action
Next article： Supreme Court strikes down use of affirmative action
.png?upscale=true&width=1212&upscale=true&name=vTFET-vaccine-makers-surge-on-bird-flu-fears(3).png)
